Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06347900
Status:
RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-03-27
Brief Title:
Corneal Topographic Changes in Different Grades of OSA
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Corneal Topographic Changes in Different Grades of Obstructive Sleep Apnea Syndrome
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Corneal topographic parameters in different degrees of obstructive sleep apnea
Detailed Description:
Obstructive sleep apnea OSA syndrome is a disease characterized by recurrent total or partial upper airway collapse during sleep interrupting or reducing the airflow and after ward resulting in temporary awakening which causes restoration of flow of the upper airway These intermittent complete apnea or partial hypopnea respiratory cessations decrease blood oxygen levels hypoxia
Upper airway stenosis causes hypoxemia and hypercapnia which can lead to multiple organ dysfunction and is associated with systemic diseases such as hypertension diabetes and coronary arteriosclerosis and changes in the eyes include floppy eyelid syndrome keratoconus and glaucoma
The prevalence of OSA is between 2 and 10 in females and 4-20 in males and obesity is a major risk factor for the development of OSA
With all the adverse effects associated with OSA its secondary effects cause several ocular complications Previous studies have shown that OSA is associated with increased risks of several vision-threatening and nonthreatening ocular disorders including senile cataracts normal-tension glaucoma retinal ischemia conjunctival hyperemia and dry eye
Several contributory mechanisms to the ocular complications of OSA have been reported including intermittent hypoxia oxidative stress systemic inflammatory responses such as interleukin-6 IL-6 IL-8 tumor necrosis factor-alpha TNF-α C-Reactive protein CRP matrix metalloproteinase 9 MMP-9 vascular cell adhesion molecule VCAM intercellular adhesion molecule ICAM selectins sympathetic system overaction damage effects of endothelin-1 and disruption of the blood-retinal barrier BRB 6-8 There are limited publications that manipulate the corneal topographic parameters in different degrees of OSA especially in the Egyptian population
Upper airway stenosis causes hypoxemia and hypercapnia which can lead to multiple organ dysfunction and is associated with systemic diseases such as hypertension diabetes and coronary arteriosclerosis and changes in the eyes include floppy eyelid syndrome keratoconus and glaucoma
The prevalence of OSA is between 2 and 10 in females and 4-20 in males and obesity is a major risk factor for the development of OSA
With all the adverse effects associated with OSA its secondary effects cause several ocular complications Previous studies have shown that OSA is associated with increased risks of several vision-threatening and nonthreatening ocular disorders including senile cataracts normal-tension glaucoma retinal ischemia conjunctival hyperemia and dry eye
Several contributory mechanisms to the ocular complications of OSA have been reported including intermittent hypoxia oxidative stress systemic inflammatory responses such as interleukin-6 IL-6 IL-8 tumor necrosis factor-alpha TNF-α C-Reactive protein CRP matrix metalloproteinase 9 MMP-9 vascular cell adhesion molecule VCAM intercellular adhesion molecule ICAM selectins sympathetic system overaction damage effects of endothelin-1 and disruption of the blood-retinal barrier BRB 6-8 There are limited publications that manipulate the corneal topographic parameters in different degrees of OSA especially in the Egyptian population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None